{"entity":{"id":"nct06075953","kind":"trial","name":"DCIS RECAST","aka":["DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment"],"tldr":"RECAST tests whether hormone therapy and repeated scans can help identify people with ductal carcinoma in situ who can continue careful monitoring. Surgery is recommended if the study evaluations indicate it is needed.","summary":"RECAST tests whether hormone therapy and repeated scans can help identify people with ductal carcinoma in situ who can continue careful monitoring. Surgery is recommended if the study evaluations indicate it is needed.\n\nInterventional study registered as NCT06075953, sponsored by QuantumLeap Healthcare Collaborative. Registry phase: 2. Registry enrollment is 400 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"recruiting","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT06075953","url":"https://clinicaltrials.gov/study/NCT06075953"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT06075953"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["elacestrant","exemestane","letrozole","tamoxifen"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06075953","phase":"2","setting":"Ductal carcinoma in situ managed with hormone therapy and active surveillance","sponsor":"QuantumLeap Healthcare Collaborative","participation":[{"nct":"NCT06075953","source":"https://clinicaltrials.gov/study/NCT06075953","fetchedAt":"2026-10-10T20:54:18.265436Z","studySha256":"14bf7aed65c56ba75185de23017fe08323c831ce74f99984de978826b983433f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-28","leadSponsor":"QuantumLeap Healthcare Collaborative","collaboratorCount":0,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":400,"enrolmentType":"ESTIMATED","siteCount":29,"recruitingSiteCount":26,"countries":["United States"]}],"started":"2024-02-17","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06075953/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/"},{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/"},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/"},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}